Structural analysis between arsenic and CYP2C8 enzyme interaction by docking

被引：0
|
作者：
Rangel Lopez, A. [1 ,2 ]
Nieto Delgado, G. [2 ]
Vertiz Hernandez, A. [1 ,2 ]
Terrones Gurrola, R. [1 ,2 ]
机构：
[1] Univ Autonoma San Luis Potosi, Matehuala, Mexico
[2] Univ Autonoma San Luis Potosi, San Luis Potosi, Mexico
来源：
JOURNAL OF NEUROCHEMISTRY | 2013年 / 125卷
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：164 / 164
页数：1
相关论文
共 50 条
  • [31] Global variation in CYP2C8–CYP2C9 functional haplotypes
    William C Speed
    Soonmo Peter Kang
    David P Tuck
    Lyndsay N Harris
    Kenneth K Kidd
    The Pharmacogenomics Journal, 2009, 9 : 283 - 290
  • [32] Linkage disequilibrium between the CYP2C19*17 and CYP2C8*2 alleles in populations of African descent
    Guilherme Suarez-Kurtz
    European Journal of Clinical Pharmacology, 2011, 67 : 211 - 212
  • [33] Linkage disequilibrium between the CYP2C19*17 and CYP2C8*2 alleles in populations of African descent
    Suarez-Kurtz, Guilherme
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 67 (02) : 211 - 212
  • [34] Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide
    Kajosaari, LI
    Jaakkola, T
    Neuvonen, PJ
    Backman, JT
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (03) : 217 - 223
  • [35] Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide
    Lauri I. Kajosaari
    Tiina Jaakkola
    Pertti J. Neuvonen
    Janne T. Backman
    European Journal of Clinical Pharmacology, 2006, 62 : 217 - 223
  • [36] Drug-drug Interaction between Losartan and Paclitaxel in Human Liver Microsomes with Different CYP2C8 Genotypes
    Mukai, Yuji
    Senda, Asuna
    Toda, Takaki
    Hayakawa, Toru
    Eliasson, Erik
    Rane, Anders
    Inotsume, Nobuo
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2015, 116 (06) : 493 - 498
  • [37] Rapid identification of CYP2C8 polymorphisms by high resolution melting analysis
    Chang, Chun-Chi
    Lin, Pei-Chin
    Lin, Ching-Hsiung
    Yeh, Kun-Tu
    Hung, Hsiao-Yu
    Chang, Jan-Gowth
    CLINICA CHIMICA ACTA, 2012, 413 (1-2) : 298 - 302
  • [38] CYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast
    Karonen, Tiina
    Neuvonen, Pertti J.
    Backman, Janne T.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 73 (02) : 257 - 267
  • [39] Discovery of a Novel Allelic Variant of CYP2C8, CYP2C8*11, in Asian Populations and Its Clinical Effect on the Rosiglitazone Disposition In Vivo
    Yeo, Chang-Woo
    Lee, Su-Jun
    Lee, Sang Seop
    Bae, Soo Kyung
    Kim, Eun-Young
    Shon, Ji-Hong
    Rhee, Byoung Doo
    Shin, Jae-Gook
    DRUG METABOLISM AND DISPOSITION, 2011, 39 (04) : 711 - 716
  • [40] EFFECT OF CYP2C9 AND CYP2C8 POLYMORPHISMS ON PHARMACOKINETICS OF IBUPROFEN ENANTIOMERS
    Abad-Santos, F.
    Ochoa, D.
    Prieto-Perez, R.
    Roman, M.
    Talegon, M.
    Rivas, A.
    Cabaleiro, T.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2014, 115 : 23 - 23
12345